- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02901145
Nivolumab in Relapsed Pediatric Solid Tumors
A Phase I/II Clinical Trial of Nivolumab in Progressive/Relapsed Pediatric Solid Tumors
patients with progressive/relapsed solid tumors who failed first line therapy , will be treated biweekly with the anti PD1- Nivolumab. at least one month after treatment initiation low dose cyclophosphamide will be started .
patients on trial will submit tissue and blood tests for whole exome an immune genomic signature. patients will also undergo repeated immunophenotype as part of follow up.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Programmed cell death 1 (PD-1) is an inhibitory receptor that prevents immune activation. PD-1 blockade can mediate reactivation of immune mediated tumor killing leading to tumor regression . Another mechanism of tumor associated immune inactivation is elevation of rates of T regulatory cells. This process may be prevented by treatment with low dose cyclophosphamide.
Objective:
This study will evaluate safety and tolerability of the anti PD1 antibody Nivolumab combined with other immunomodulating treatments, in pediatric patients with relapsed/progressive solid tumors
Method:
Patients will be treated with IV Nivolumab 3mg/kg over 60 minutes on day 1 and 15 of each cycle of 28 days.
Dose finding phase:
- Six patients will be accrued for the first cohort and treated for 1 month
- If an adverse event >grade 2 will occur in>2 patients, study medication dose will be reduced by 25% and another cohort of 6 patients will be accrued on the reduced dose.
- Dose finding cohorts will be accrued until determination of a dose with allowed DLT
Expansion phase
- Following dose determination patients will be accrued, to the final number of 30 patients
- Cyclophosphamide at the dose of 50 mg/dayx7days every 14 days (one week on one week off ) will be started . immunophenotype will be done every 28 days and dose of cyclophosphamide will be elevated by 25mg /day every month until highest ratio of CD8/CD25FOXP3 cells will be reached for every child
- All patients will be treated for 1 year or until imaging proven disease progression.
Required follow up
- All patients will undergo tumor bed imaging (CT/MRI-based on tumor location) with metastatic evaluation (according to standar follow up) every 4 months
- Tumor response will be measured based on RECIST criteria
- Toxicity assessment will be done according to the CTCAE v. 4.03
c. Collateral studies:
- Immunohistochemical analysis for PD1 and PDL1 will be done on pretreatment paraffin embedded tissue to estimate it's ability to predict response.
- Immune profile of peripheral blood lymphocytes including CD3+, CD4+, CD8+ FOX P3+ cells and it's correlation to objective response to therapy.
- Exome sequencing of the tumor and peripheral blood will be done for every patient.
Exome will be evaluated for driver mutations and immunologic genomic signature.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Iris Fried, MD
- Phone Number: 508573151
- Email: ishonet@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages Eligible for Study: 12 Months and older
Patients must have had histologic verification of malignancy at original diagnosis or relapse
Eligible pathologies:
- neuroblastoma following lack of complete response to at least two lines of therapy
- rhabdomyosarcoma following progression after first line therapy
- Ewing sarcoma following progression after second line of therpy
- Osteosarcoma following progression after first line of therapy all other pathologies will be discussed with PI
- Patients must have measurable disease
- Patient's current disease state must be one for which there is no known curative therapy
- Karnofsky >= 50 for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer treatment
- At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)
- At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
- at least 56 days must have elapsed after transplant or stem cell infusion; patients with prior allogeneic transplants are not eligible
- Blood counts recovery including ANC >= 750/mm^3 and Platelet count >= 50,000/mm^3
- Creatinine clearance ≤ 1.5 ULN
- liver function:Total bilirubin ≤ 2 ULN, ALT or AST ≤ 2.5 ULN (or < 5 in case of liver impairment)
- Life expectancy of at least 4 months
Pregnancy:
- Negative pregnancy test in women of childbearing potential
- Use of an effective contraceptive method during the whole treatment and
- up to 3 months after the completion of treatment in males and females
- prior informed consent signed
Exclusion Criteria:
- Patients requiring daily systemic corticosteroids are not eligible; patients must not have received systemic corticosteroids within 7 days of enrollment on study
- Patients who are currently receiving another investigational drug are not eligible
- Patients who are currently receiving other anti-cancer agents are not eligible
- Patients with a history of any grade autoimmune disorder are not eligible; asymptomatic laboratory abnormalities (e.g. antinuclear antibody [ANA], rheumatoid factor, altered thyroid function studies) will not render a patient ineligible in the absence of a diagnosis of an autoimmune disorder
- Patients with >= grade 2 hypothyroidism due to history of autoimmunity are not eligible; note: hypothyroidism due to previous irradiation on thyroidectomy will not impact eligibility
- Patients who have an uncontrolled infection are not eligible.
- Patients with active autoimmune disease. (any autoimmune state requiring medical treatment-including chronic medications)all immune modifying drugs should be stopped at least 7 days prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: progressive/relapsed solid tumors
patient with progressive/relapsed solid tumors who failed first line therapy
|
treatment with IV Nivolumab 3mg/kg every 2 weeks .
after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event free survival
Time Frame: 6 months
|
Rate of patients with stable disease/tumor response at 6 months
|
6 months
|
Overall survival
Time Frame: 6 and 12 months
|
Rate of patients alive at 6 months and 12 months
|
6 and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
evaluation of predictors for response
Time Frame: 12 months
|
correlation between levels of PD1 receptor expression in the tumor and genomic signature with response
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Cyclophosphamide
- Nivolumab
Other Study ID Numbers
- 0506-15-HMO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antibodies, Neoplasm
-
Odense University HospitalRecruiting
-
Nanfang Hospital of Southern Medical UniversityRecruitingDrug-specific AntibodiesChina
-
Christopher O'Brien, MDBioIncept LLCWithdrawnPanel Reactive Antibodies
-
Scripps Translational Science InstituteCompletedAntibodies Involved in Healthy AgingUnited States
-
Hannover Medical SchoolRecruitingLung Transplantation | Donor-specific Anti-human Leukocyte Antigen(HLA) AntibodiesGermany
-
DatabeanOctapharmaTerminatedRenal Transplant Recipients With Anti-HLA AntibodiesUnited States
-
University Hospital, Strasbourg, FranceRecruitingLung Transplant Recipient | Antibody Mediated Rejection | Donor Specific AntibodiesFrance
-
Aga Khan UniversityThe Hospital for Sick Children; Grand Challenges CanadaCompletedRhesus Disease | Anti-D (Rh) Antibodies Affecting Care of MotherPakistan
-
South Valley UniversityActive, not recruiting
-
Children's Hospital of Chongqing Medical UniversityRecruitingPassive Transmission of Maternal and Infant AntibodiesChina
Clinical Trials on Nivolumab,low dose cyclophosphamide
-
Masonic Cancer Center, University of MinnesotaCompletedAcute Myeloid Leukemia | Higher Risk Myelodysplastic SyndromeUnited States
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsActive, not recruiting
-
Merck KGaA, Darmstadt, GermanyCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
Hospital Universitario Dr. Jose E. GonzalezRecruitingSafety Issues | Efficacy, SelfMexico
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
Diwakar DavarAculeus TherapeuticsActive, not recruitingNSCLC | Metastatic Colorectal Carcinoma | Refractory MelanomaUnited States
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom